But a potentially more interesting advisory committee, for Merck and Ridgeback’s molnupiravir, awaits.
Merus regains some lost pride while Bicycle rides to even greater heights.
M&A picked up in the third quarter but overall 2021 has been quiet on the takeover front.
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
Two Xencor approaches with questions around them receive the backing of Johnson & Johnson.
Molnupiravir, a repurposed flu antiviral with a poor history, delivers in a pivotal study in Covid-19 outpatients.